EquitiesIndia.com

Healthcare · Drug Manufacturers - Specialty & Generic

Mankind Pharma Ltd.

MANKIND

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Key metrics

Market Cap

₹85,827 cr

P/E Ratio

48.08x

P/B Ratio

5.99x

ROE

13.89%

ROCE

12.86%

Debt / Equity

0.59x

Net Margin

16.31%

Dividend Yield

10%

EPS

₹49.2

Period

FY2025

Shareholding pattern

As of Latest
Promoter: 75.27%FII: 17.86%Public: 6.87%

Deep-dive pages

Educational content — not investment adviceThis page presents publicly available information about Mankind Pharma Ltd. for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing here constitutes investment advice, a recommendation to buy or sell any security, or a solicitation to transact. All financial data shown is sourced from public BSE/NSE filings and is at least 90 days old. Past performance is not indicative of future results. Please consult a SEBI-registered adviser before making any investment decision.